This site is intended for healthcare professionals
Anticoagulation Therapy for Stroke Prevention
Declaration of sponsorship Pfizer and Bristol Myers Squibb


Declaration of sponsorship Pfizer and Bristol Myers Squibb
Read time: 250 mins
Last updated:12th Mar 2020
Welcome to the Anticoagulation Therapy for Stroke Prevention Learning Zone, which introduces the intimate relationship between stroke and atrial fibrillation (AF). Warfarin reduces stroke risk in AF patients, but commonly causes major bleeds and other side effects. The need for regular monitoring and the risk of interactions often makes warfarin difficult to use clinically. Oral non-vitamin K antagonists transformed anticoagulant therapy for non-valvular AF offering improved efficacy and tolerability compared with warfarin. 

This Learning Zone reviews the epidemiology, pathophysiology, diagnosis and management of atrial fibrillation, including the latest anticoagulant guidelines, to help you balance the risks and benefits of the various invasive and pharmacological options. 

The Learning Zone helps you deliver optimal care and prevent strokes in your patients living with common sustained cardiac arrhythmia.


Register for free exclusive healthcare eLearning resources

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest